Dupilumab, an anti-IL-4Rα monoclonal antibody, inhibits IL-4/IL-13 signaling, key drivers of type 2/Th2 immune diseases (e.g. atopic/allergic disease). In a pivotal, phase 2b study (NCT01854047), dupilumab reduced severe exacerbations, improved lung function and quality of life, and was generally well tolerated in patients with uncontrolled persistent asthma despite using medium-to-high-dose inhaled corticosteroids plus long-acting β2-agonists.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2DmEDFG
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Epilepsy is a serious neurological disorder which disturbs the common activities of a human brain. It is detected with the help o...
-
The main idea behind this work was demonstrated in a form of a new thermoelectrochromic sensor on a flexible substrate using graphene as an ...
-
The paper proposes a multicriteria decision analysis (MCDA) framework for a comparative evaluation of nuclear waste management strategies ta...
-
Abstract There are many unanswered questions about giant cell tumor (GCT) treatment and not enough attention is paid to the biomechanics o...
-
Tuberculosis (TB) is one of the leading causes of death worldwide, especially in developing countries. Neonatal BCG vaccination occurs in va...
-
Bearing faults are the biggest single source of motor failures. Artificial Neural Networks (ANNs) and other decision support systems are wid...
-
Tetracycline Repressors (TetRs) modulate multi-drug efflux pathways in several pathogenic bacteria. In Streptomyces, they additionally regul...
-
LETTER TO EDITOR Year : 2019 | Volume : 63 | Issue : 2 | Page : 150-151 Unseen complication of the exhausted soda lime Deepak...
-
Abstract Recently, food recommender systems have received increasing attention due to their relevance for healthy living. Most existing st...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου